SaRS-Cov-2 Antibodies Following Exposure to Coronavirus Disease 2019 (COVID-19) and/or Vaccination in Nursing Homes

Sponsor

Central Hospital, Nancy, France (Other)

Overall Status

Completed

CT.gov ID

NCT04964024

Collaborator

(none)

1,293

Enrollment

Location

Actual Duration (Months)

129.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Presence of SaRS-Cov-2 antibodies following exposure to Coronavirus Disease 2019 (COVID-19) and/or vaccination is a major indicator of immunization. Few data exit about serology response in nursing homes (NHs), i.e. in the most vulnerable population for developing severe forms of the disease.

Residents and health professionals in 9 nursing homes (NHs) with SaRS-Cov-2 antibodies detection after exposure (either COVID-19 or vaccine) All biological tests were performed in the frame of the standard care of residents and health professionals and all participants did not express opposition for using anonymously their data for the purpose of this academic analysis. In addition all Directors and Physicians of these NHs accepted to participate in this study

Condition or Disease	Intervention/Treatment	Phase
COVID-19 Infection	Diagnostic Test: SARS-CoV-2 antibodies

Study Design

Study Type:

Observational

Actual Enrollment :

1293 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

SaRS-Cov-2 Antibodies Following Exposure to COVID-19 and/or Vaccination in Nursing Homes

Actual Study Start Date :

Jul 15, 2021

Actual Primary Completion Date :

May 15, 2022

Actual Study Completion Date :

May 15, 2022

Arms and Interventions

Arm	Intervention/Treatment
Residents in Nursing homes	Diagnostic Test: SARS-CoV-2 antibodies Analysis of the results of the serological response to COVID-19 and/or Vaccine
Health professionals in Nursing homes	Diagnostic Test: SARS-CoV-2 antibodies Analysis of the results of the serological response to COVID-19 and/or Vaccine

Arm

Intervention/Treatment

Residents in Nursing homes

Diagnostic Test: SARS-CoV-2 antibodies

Analysis of the results of the serological response to COVID-19 and/or Vaccine

Health professionals in Nursing homes

Diagnostic Test: SARS-CoV-2 antibodies

Analysis of the results of the serological response to COVID-19 and/or Vaccine

Outcome Measures

Primary Outcome Measures

Levels of SARS-COV-2 antibodies [Through study completion average 6 months Retrospective analysis]
Study of the SARS-COV-2 antibodies according to the history of COVID-19 and vaccinal status in Nursing Home residents and in health professionals

Eligibility Criteria

Criteria

Ages Eligible for Study:

20 Years to 110 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

For Residents:

Living in one of the 9 Nursing Homes that participate in this study
Having a SARS-COV-2 post vaccination serology.
Having no objection for using the results of the serology for the purpose of this analysis

For Health Professionals:

Working in one of the 9 Nursing Homes that participate in this study,
Having a SARS-COV-2 post vaccination serology.
Having no objection for using the results of the serology for the purpose of this analysis

Exclusion Criteria:

None

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	CHRU de Nancy, Université de Lorraine	Vandoeuvre les Nancy	US And Canada Only	France	54500

Sponsors and Collaborators

Central Hospital, Nancy, France

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Pr Athanase BENETOS, Athanase Benetos, Clinical Professor, Head of the Dpt of Geriatrics, Central Hospital, Nancy, France

ClinicalTrials.gov Identifier:

NCT04964024

Other Study ID Numbers:

EHPAD-COVID-19

First Posted:

Jul 15, 2021

Last Update Posted:

Jul 19, 2022

Last Verified:

Jul 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Undecided

Plan to Share IPD:

Undecided

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Pr Athanase BENETOS, Athanase Benetos, Clinical Professor, Head of the Dpt of Geriatrics, Central Hospital, Nancy, France

Additional relevant MeSH terms:

COVID-19

Antibodies

Study Results

No Results Posted as of Jul 19, 2022